Frontlight ResearchEarly access
CompletedPhase 1
Intraoperative Midazolam on Delirium Outcome of Elderly Patients
Key facts
- Who runs it
- Chinese PLA General Hospital
- Where
- China5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 612 people enrolled
- Started
- 1 Sept 2025
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Midazolam
- Saline
- Record updated
- 2 September 2026
Who can take part
- Age
- 65 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- 65 ≤ Age ≤ 85 years old
- Elective surgery under general anesthesia, with an estimated surgery time of ≥ 2 hours
- Non cardiac surgery, non neurosurgical surgery
- ASA grades I-III
- Agree to participate and sign the informed consent form
Who cannot take part
- Long term use of benzodiazepines before surgery
- Patients expected to enter the ICU after surgery
- Preoperative history of comorbidities such as depression and schizophrenia
- History of neurological disorders, moderate stroke
- There is cognitive impairment, which is determined based on Mini Mental State Examination (MMSE) scores below the standard threshold
- There are communication barriers, such as severe dementia, language barriers, and severe hearing or visual impairments
- There are any contraindications for the use of midazolam (contraindications for patients with severe respiratory dysfunction, patients with severe liver and kidney damage, patients with sleep apnea syndrome, and patients known to be allergic to benzodiazepines)
- BMI≤18.5/BMI≥30 kg/m2
- Preoperative severe liver and kidney dysfunction
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study was a multicenter, randomized, double-blind, placebo-controlled trial to treat elderly surgical patients with low-dose midazolam or placebo for anesthesia induction. The incidence of postoperative 7-day delirium was assessed and compared between two groups, to provide valuable reference for clinical practitioners in the use of midazolam in elderly surgical patients.
The 2 groups in the trial
- Saline groupPlacebo, for comparison
The control group patients were given 2 mL physiological saline during anesthesia induction.
Treatment: Saline
- Midazolam groupTreatment being tested
The intervention group patients were given 2mg midazolam injection (Jiangsu Enhua Pharmaceutical Co., Ltd.) during anesthesia induction
Treatment: Midazolam
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impact of Intraoperative Midazolam on Delirium Outcome of Elderly Patients (I-IMODE): a Multicentre Randomised Controlled Trial
- Record updated
- 2 September 2026